Correction: Tsoi et al. Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer. Life 2022, 12, 93
Error in Figure
Reference
- Tsoi, H.; Shi, L.; Leung, M.-H.; Man, E.P.S.; So, Z.-Q.; Chan, W.-L.; Khoo, U.-S. Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer. Life 2022, 12, 93. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tsoi, H.; Shi, L.; Leung, M.-H.; Man, E.P.S.; So, Z.-Q.; Chan, W.-L.; Khoo, U.-S. Correction: Tsoi et al. Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer. Life 2022, 12, 93. Life 2024, 14, 1044. https://doi.org/10.3390/life14081044
Tsoi H, Shi L, Leung M-H, Man EPS, So Z-Q, Chan W-L, Khoo U-S. Correction: Tsoi et al. Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer. Life 2022, 12, 93. Life. 2024; 14(8):1044. https://doi.org/10.3390/life14081044
Chicago/Turabian StyleTsoi, Ho, Ling Shi, Man-Hong Leung, Ellen P. S. Man, Zi-Qing So, Wing-Lok Chan, and Ui-Soon Khoo. 2024. "Correction: Tsoi et al. Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer. Life 2022, 12, 93" Life 14, no. 8: 1044. https://doi.org/10.3390/life14081044